Trial Profile
A Multi-center, One-arm Clinical Study of Anlotinib Combined With Icotinib as the First-line Treatment in Patients With EGFR Mutation-positive Advanced NSCLC. The Trial Aims to Evaluate the Efficacy and Safety of This Treatment
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Nov 2021
Price :
$35
*
At a glance
- Drugs Catequentinib (Primary) ; Icotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms ALTER-L004
- 21 Sep 2021 Results presented at the 46th European Society for Medical Oncology Congress
- 11 Mar 2021 Status changed from recruiting to completed.
- 21 Sep 2020 Results of a updated analysis presented at the 45th European Society for Medical Oncology Congress